Yin and yang of the plasminogen activator inhibitor

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 6, 2009, Pages 410-417

  Jankun, Jerzy ^a,b   Skrzypczak Jankun, Ewa ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Cancer; High level of PAI 1; PAI 1 deficiency; Plasminogen activator inhibitor (PAI)

Indexed keywords

PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLASMINOGEN ACTIVATOR INHIBITOR 3; VITRONECTIN;

ANGIOGENESIS; CHINESE MEDICINE; HUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW;

EID: 67650463090     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.729     Document Type: Review

References (89)

1. Iishi H, Tatsuta M, Baba M, et al. Suppression by amiloride of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane. Int J Cancer. 1995; 63: 716-719.
2. Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol. 1988; 107: 2437-2445.
3. Ngo TH, Hoylaerts MF, Knockaert I, et al. Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitor properties concomitant with an allosteric up-regulation of its antiadhesive properties. J Biol Chem. 2001; 276: 26243-26248. (Pubitemid 37412839)
4. Kwaan HC, Keer HN, Radosevich JA, et al. Components of the plasminogen-plasmin system in human tumor cell lines. Semin Thromb Hemost. 1991; 17: 175-182.
5. Berkenpas MB, Lawrence DA, Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 1995; 14: 2969-2977.
6. Tucker HM, Mottonen J, Goldsmith EJ, et al. Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nat Struct Biol. 1995; 2: 442-445.
7. Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, et al. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther. 2003; 2: 19-28.
8. Fay WP, Parker AC, Condrey LR, et al. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood. 1997; 90: 204-208. (Pubitemid 27276563)
9. Lee MH, Vosburgh E, Anderson K, et al. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood. 1993; 81: 2357-2362. (Pubitemid 23127070)
10. Mehta R, Shapiro AD. Plasminogen activator inhibitor type 1 deficiency. Haemophilia. 2008; 14: 1255-1260.
11. Morimoto Y, Yoshioka A, Imai Y, et al. Haemostatic management of intraoral bleeding in patients with congenital deficiency of alpha2-plasmin inhibitor or plasminogen activator inhibitor-1. Haemophilia. 2004; 10: 669-674. (Pubitemid 39317778)
12. Largent V, Deneys V, Brichard B, et al. Bleeding diathesis in a child with normal screening tests: think about fibrinolysis. Eur J Pediatr. 2005; 164: 587-588. (Pubitemid 41225066)
13. Kuhli C, Luchtenberg M, Scharrer I, et al. Massive subhyaloidal hemorrhage associated with severe PAI-1 deficiency. Graefes Arch Clin Exp Ophthalmol. 2005; 243: 963-966. (Pubitemid 41631034)
14. Takahashi Y, Tanaka T, Minowa H, et al. Hereditary partial deficiency of plasminogen activator inhibitor-1 associated with a lifelong bleeding tendency. Int J Hematol. 1996; 64: 61-68. (Pubitemid 26228570)
15. Zhang ZY, Wang ZY, Fu JX, et al. [Report of a case of congenital plasminogen activator inhibitor-1 deficiency]. Zhonghua Xue Ye Xue Za Zhi. 2004; 25: 129-131. Chinese.
16. Schleef RR, Higgins DL, Pillemer E, et al. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest. 1989; 83: 1747-1752. (Pubitemid 19124134)
17. Agren A, Kolmert T, Wiman B, et al. Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate. Thromb Res. 2007; 119: 715-721. (Pubitemid 46441426)
18. Minowa H, Takahashi Y, Tanaka T, et al. Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency. Haemostasis. 1999; 29: 286-291. (Pubitemid 30207458)
19. Agren A, Wiman B, Schulman S. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Blood Coagul Fibrinolysis. 2007; 18: 657-660. (Pubitemid 47479416)
20. Agren A, Wiman B, Stiller V, et al. Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis. J Thromb Haemost. 2006; 4: 201-208.
21. Santamaria A, Borrell M, Mateo J, et al. What is the clinical impact of low plasminogen activator inhibitor-1 (PAI-1) activity? A case report and study of the incidence of low PAI-1 antigen in a healthy population. J Thromb Haemost. 2007; 5: 1565-1566. (Pubitemid 46965392)
22. Ogston D. Current status of antihbrinolytic drugs. Blood Rev. 1989; 3: 1-4.
23. Sharifi R, Lee M, Ray P, et al. Safety and efficacy of intravesical aminocaproic acid for bleeding after transurethral resection of prostate. Urology. 1986; 27: 214-219. (Pubitemid 17052630)
24. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs. 1985; 29: 236-261.
25. Athanasiadis T, Beule AG, Wormald PJ. Effects of topical antifibrinolytics in endoscopic sinus surgery: a pilot randomized controlled trial. Am J Rhinol. 2007; 21: 737-742.
26. Jankun J, Aleem AM, Specht Z, et al. PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. Int J Mol Med. 2007; 20: 11-20.
27. Lim JH, Stirling B, Deny J, et al. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity. 2007; 27: 349-360. (Pubitemid 47284927)
28. Renckens R, Roelofs JJ, Bonta PI, et al. Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia. Blood. 2007; 109: 1593-1601. (Pubitemid 46239593)
29. Bajt ML, Yan HM, Farhood A, et al. Plasminogen Activator Inhibitor-1 Limits Liver Injury and Facilitates Regeneration after Acetaminophen Overdose. Toxicol Sci. 2008. (Pubitemid 352038264)
30. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost. 2009; 7: 4-13.
31. Katz BA, Mackman R, Luong C, et al. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. Chem Biol. 2000; 7: 299-312. (Pubitemid 30199618)
32. Smolarczyk K, Boncela J, Szymanski J, et al. Fibrinogen contains cryptic PAI-1 binding sites that are exposed on binding to solid surfaces or limited proteolysis. Arterioscler Thromb Vasc Biol. 2005; 25: 2679-2684. (Pubitemid 43732297)
33. Reilly CF, Hutzelmann JE. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution. J Biol Chem. 1992; 267: 17128-17135.
34. Swiercz R, Keck RW, Skrzypczak-Jankun E, et al. Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep. 2001; 8: 463-470. (Pubitemid 33758438)
35. Swiercz R, Skrzypczak-Jankun E, Merrell MM, et al. Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol Rep. 1999; 6: 523-526.
36. Jankun J, Aleem AM, Selman SH, et al. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. Int J Mol Med. 2007; 20: 683-687.
37. Jankun J, Aleem AM, Struniawski R, et al. Accelerated thrombus lysis in blood of plasminogen activator inhibitor deficient mice is inhibited by very long half-life PAI-1. Pharmacol Rep. [In press].
38. Mlynarska A, Waszyrowski T, Kasprzak JD. Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI-1 gene. J Thromb Haemost. 2006; 4: 1361-1366. (Pubitemid 43756717)
39. Stegnar M, Uhrin P, Peternel P, et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost. 1998; 79: 975-979. (Pubitemid 28224735)
40. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993; 268: 10739-10745. (Pubitemid 23162248)
41. Jood K, Ladenvall P, Tjamlund-Wolf A, et al. Fibrinolytic gene polymorphism and ischemic stroke. Stroke. 2005; 36: 2077-2081. (Pubitemid 41429223)
42. Ma LJ, Fogo AB. PAI-1 and kidney fibrosis. Front Biosci. 2009; 14: 2028-2041.
43. Schenk JF, Stephan B, Zewinger S, et al. Comparison of the plasminogen activator inhibitor-1 4G/5G gene polymorphism in females with venous thromboembolism during pregnancy or spontaneous abortion. Clin Hemorheol Microcirc. 2008; 39: 329-332. (Pubitemid 352040013)
44. Schalkwijk CG, Stehouwer CD. PAI-1 inhibition in obesity and the metabolic syndrome: a promising therapeutic strategy. Thromb Haemost. 2006; 96: 698-699. (Pubitemid 44883807)
45. Sola E, Vaya A, Espana F, et al. Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism. Thromb Res. 2008; 122: 320-327.
46. Shammaa DM, Sabbagh AS, Taher AT, et al. Plasminogen Activator Inhibitor-1 (PAI-1) gene 4G/5G alleles frequency distribution in the Lebanese population. Mol Biol Rep. 2008; 35: 453-457.
47. Glueck CJ, Goldenberg N, Wang P, et al. Ramifications of four concurrent thrombophilic mutations and one hypofibrinolytic mutation. Clin Appl Thromb Hemost. 2004; 10: 365-371. (Pubitemid 39391297)
48. De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol. 2005; 5: 149-154.
49. Crandall DL, Quinet EM, El Ayachi S, et al. Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol. 2006; 26: 2209-2215. (Pubitemid 44465713)
50. Lijnen HR, Alessi MC, Frederix L, et al. Tiplaxtinin impairs nutritionally induced obesity in mice. Thromb Haemost. 2006; 96: 731-737. (Pubitemid 44883812)
51. Huang Y, Border WA, Yu L, et al. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol. 2008; 19: 329-338. (Pubitemid 351240654)
52. Vaisanen SB, Humphries SE, Luong LA, et al. Regular exercise, plasminogen activator inhibitor-1 (PAI-1) activity and the 4G/5G promoter polymorphism in the PAI-1 gene. Thromb Haemost. 1999; 82: 1117-1120. (Pubitemid 29419729)
53. Homebeck W, Emonard H, Monboisse JC, et al. Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin Cancer Biol. 2002; 12: 231-241. (Pubitemid 34833066)
54. Leake D, Doerr TD, Scott G. Expression of urokinase-type plasminogen activator and its receptor in keloids. Arch Otolaryngol Head Neck Surg. 2003; 129: 1334-1338. (Pubitemid 37523110)
55. Weidle UH, Konig B. Urokinase receptor antagonists: novel agents for the treatment of cancer. Expert Opin Investig Drugs. 1998; 7: 391-403. (Pubitemid 28105619)
56. Stephens RW, Brunner N, Janicke F, et al. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat. 1998; 52: 99-111. (Pubitemid 29056088)
57. Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res. 1996; 2: 613-618.
58. Conese M, Blasi F. The urokinase/urokinase-receptor system and cancer invasion. Baillieres Clin Haematol. 1995; 8: 365-389.
59. Achbarou A, Kaiser S, Tremblay G, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 1994; 54: 2372-2377. (Pubitemid 24138727)
60. Festuccia C, Vincentini C, di Pasquale AB, et al. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncol Res. 1995; 7: 131-138.
61. Wilson MJ, Sinha AA. Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior. Cell Mol Biol Res. 1993; 39: 751-760.
62. Pepper MS, Sappino AP, Stocklin R, et al. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol. 1993; 122: 673-684. (Pubitemid 23226684)
63. Jankun J, Keck RW, Skrzypczak-Jankun E, et al. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res. 1997; 57: 559-563. (Pubitemid 27085630)
64. Goodson RJ, Doyle MV, Kaufman SE, et al. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci U S A. 1994; 91: 7129-7133. (Pubitemid 24226816)
65. Ignjatovic Z, Nikolic L. [Inhibition of angiogenesis in the cornea with amiloride]. Srp Arh Celok Lek. 1996; 124: 120-123.
66. Mars WM, Zamegar R, Michalopoulos GK. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol. 1993; 143: 949-958. (Pubitemid 24058250)
67. Hart CA, Scott LJ, Bagley S, et al. Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. Br J Cancer. 2002; 86: 1136-1142. (Pubitemid 34438087)
68. Billstrom A, Hartley-Asp B, Lecander I, et al. The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice. Int J Cancer. 1995; 61: 542-547.
69. Kermorgant S, Aparicio T, Dessirier V, et al. Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement. Carcinogenesis. 2001; 22: 1035-1042.
70. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate. 1999; 39: 246-261. (Pubitemid 29244499)
71. Sparks RL, Pool TB, Smith NK, et al. Effects of amiloride on tumor growth and intracellular element content of tumor cells in vivo. Cancer Res. 1983; 43: 73-77. (Pubitemid 13172797)
72. Dano K, Behrendt N, Hoyer-Hansen G, et al. Plasminogen activation and cancer. Thromb Haemost. 2005; 93: 676-681.
73. Jedinak A, Maliar T. Inhibitors of proteases as anticancer drugs. Neoplasma. 2005; 52: 185-192.
74. Jankun J, Skrzypczak-Jankun E. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride. Cancer Biochem Biophys. 1999; 17: 109-123. (Pubitemid 29475251)
75. Shin JS, Yu MH. Kinetic dissection of alpha 1-antitrypsin inhibition mechanism. J Biol Chem. 2002; 277: 11629-11635. (Pubitemid 34952713)
76. Ding X, Rasmussen BF, Demuth HU, et al. Nature of the inactivation of elastase by N-peptidyl-O-aroyl hydroxylamine as a function of pH. Biochemistry. 1995; 34: 7749-7756.
77. Lawrence DA, Olson ST, Palaniappan S, et al. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition. J Biol Chem. 1994; 269: 27657-27662. (Pubitemid 24346602)
78. McMahon GA, Petitclerc E, Stefansson S, et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem. 2001; 276: 33964-33968. (Pubitemid 37384622)
79. Stefansson S, McMahon GA, Petitclerc E, et al. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des. 2003; 9: 1545-1564. (Pubitemid 36763492)
80. Binder BR, Mihaly J. The plasminogen activator inhibitor "paradox" in cancer. Immunol Lett. 2008; 118: 116-124.
81. Stefansson S, Petitclerc E, Wong MK, et al. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem. 2001; 276: 8135-8141. (Pubitemid 37385618)
82. Noel A BK, Masson V, Devy L, Frankenne F, Rakic JM, Lambert V, Carmeliet P, Foidart JM. Regulation of Cancer Invasion and Vascularization by Plasminogen Activator Inhibitor-1. Fibrynolysis and Proteolysis. 1999: 220-225. (Pubitemid 30190395)
83. Degryse B, Sier CF, Resnati M, et al. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. FEBS Lett. 2001; 505: 249-254. (Pubitemid 32896675)
84. Quax PH, Grimbergen JM, Lansink M, et al. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding. Arterioscler Thromb Vasc Biol. 1998; 18: 693-701. (Pubitemid 28267647)
85. Ribatti D, Leali D, Vacca A, et al. In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. J Cell Sci. 1999; 112 (Pt 23): 4213-4221.
86. Olson D, Pollanen J, Hoyer-Hansen G, et al. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem. 1992; 267: 9129-9133.
87. Estreicher A, Wohlwend A, Belin D, et al. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem. 1989; 264: 1180-1189. (Pubitemid 19038109)
88. Sipley JD, Alexander DS, Testa JE, et al. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1. Proc Natl Acad Sci U S A. 1997; 94: 2933-2938. (Pubitemid 27157242)
89. Jankun J, Skrzypczak-Jankun E. Binding site of amiloride to urokinase plasminogen activator depends on species. Int J Mol Med. 2001; 8: 365-371.